Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Any news about commercialisation of AZD1656 will propel VELA’s SP to where most of us feel it should be.
Just HODL to utilise a phrase from the crypto markets. It’ll come good in the end.
I think SGSC sold their shares to free up capital not only to pay for their accounts but also to possibly invest in phase III.
Difficult to say what a charity does with shares as they’re not an investment company as such.
Who knows… all I know is that we seem to have a steady support price of 0.7 which is comforting to have if you’ve
got money in the bank and a medicine-investment in the pipeline that actually works.
From Goldman Sachs equity research on the Merck tablet:
“” We note that the molnupiravir data from today, while encouraging in efforts to further contain the pandemic and prevent severe disease, do not yet address these topics of reduced infection spread/mild-moderate infection (we look forward to more data on this front in the future). MRK is studying molnupiravir in patients for post-exposure prophylaxis (i.e. prevention of disease in patients who have been previously exposed to COVID-19 by a household member), with data expected in 1H22 (per MRK on its 2Q earnings).
While there is the possibility that the presence of an antiviral could impact pricing (where the eventual price of an annual dose in the endemic market is another key debate for the vaccine stocks), in our view it remains early to draw a conclusion on this point and we look forward to seeing the full molnupiravir data.””
Copied from another forum:
“” WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared, the drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
AstraZeneca will want a pill to compete with this, ADZ1656 is the one.””
That means it’ll only benefit 1 million people… if it’s only 10 million tablets. That is very low - although any life saved is worth it of course.
If SGS’s tablet can be mass produced then there will be a huge market for AZD1656 to tap into at a fraction of the Merck cost.
After doing some research, if the efficacy of the Merck tablets is only 50%, then this would have been abandoned if it was a vaccine.
It might be useful to distribute across the world in places where vaccinations weren’t possible but aside from that
the current vaccines are far more effective and far cheaper.
AZD1656 actually prolongs the effect of vaccines, which will be even more economical for the NHS.
I fear that this might be more hype than actually a game changing development.
Merck might be first past the post, but to me the race hasn’t been lost.
“” At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. ””
MriGoat, if we consider AZD1656 as a treatment for COVID then it’ll have competition from other tablets which do the same.
I understand the diabetic side of the trial , which is great, but in a pandemic, do we need a tablet for diabetics with COVID or a tablet for everyone with COVID. For mass adoption this will be what’s looked at. A one-for-all.
If SGS is as quick with their commercialisation deals as it is with its accounts - it looks like we will miss the boat big time on getting any pill to market before several others do.
Can’t help but feel anything but worried and deflated that it’ll all be too little too late for AZD1656. If it prolongs the effect of vaccines by 4 months or so, that’s great, but will it do so for the new pills being trialled also, regardless of variants mutation etc?
So many uncertainties with this. Wish they’d say something, either positive or negative. Keeping quiet doesn’t do any good.
This just flashed up on the LSE Board under Share News:
“ Vela Technologies PLC - Bingley, England-based investment firm focused on technology - Does not generate revenue in year to March 31 but swings to pretax profit of GBP380,000 from GBP1.4 million loss. Reports GBP666,000 gain from fair value movements on investments, compared to GBP979,000 hit the year earlier. "The company's improved position has quite naturally generated a significant flow through of new investment opportunities and each is robustly reviewed by the board for its future benefit to the Vela portfolio. We continue to remain open to new opportunities that fall within the constraints of the company's investing policy," Vela says.”
We made a profit, got money in the bank for new investments and sit on 8% of something that could potentially send the share price to the moon. Decent looking year results and RNS. Should be our support price now at 7.5. Can’t get it all right, but 2 very solid looking contenders amongst the technical summary by THGambler
I’m proper small time , and invested most of my portfolio into the SGS trial for it to produce positive results, not too interested in the rest of VELA’s investments. Just hope my hunch and research will eventually come good as I’m averaging 9 per share.
Didn’t sell on 14 and still believe that there is potential for a big result, maybe not x100 or even x20 but a x10 should be possible on a good commercial deal. Just frustrated with the management who keep so quiet it’s bordering on ridiculous.
GLA as you all say. Let’s hope it works out.
Would help if the team at VELA would release updates alongside the other companies, that VELA has investments in, when they release their RNS’s and news. They just keep quiet, it’s not helping VELA, us or the share price.
Accounts tomorrow, probably another quiet affair if their style of getting attention is anything to go by.
JN doesn’t do social media, someone said once, living in the past, and so are we now again on past share prices.